548 related articles for article (PubMed ID: 29307995)
21. Improvement of sleep architecture parameters in cirrhotic patients with recurrent hepatic encephalopathy with the use of rifaximin.
Bruyneel M; Sersté T; Libert W; van den Broecke S; Ameye L; Dachy B; Mulkay JP; Moreno C; Gustot T
Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):302-308. PubMed ID: 27977438
[TBL] [Abstract][Full Text] [Related]
22. Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome.
Yu X; Jin Y; Zhou W; Xiao T; Wu Z; Su J; Gao H; Shen P; Zheng B; Luo Q; Li L; Xiao Y
Front Cell Infect Microbiol; 2021; 11():761192. PubMed ID: 35118004
[TBL] [Abstract][Full Text] [Related]
23. A non-absorbable rifamycin for treatment of hepatic encephalopathy.
Testa R; Eftimiadi C; Sukkar GS; De Leo C; Rovida S; Schito GC; Celle G
Drugs Exp Clin Res; 1985; 11(6):387-92. PubMed ID: 3836135
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
Irimia R; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Switching from Kanamycin Sulfate to Rifaximin in Patients with Hepatic Cirrhosis.
Tatsumi R; Suii H; Yamaguchi M; Arakawa T; Nakajima T; Kuwata Y; Toyota J; Hige S
Intern Med; 2021 May; 60(10):1501-1507. PubMed ID: 33361677
[TBL] [Abstract][Full Text] [Related]
26. Changes in the Body Composition and Nutritional Status after Long-term Rifaximin Therapy for Hyperammonemia in Japanese Patients with Hepatic Encephalopathy.
Ishikawa T; Endo S; Imai M; Azumi M; Nozawa Y; Sano T; Iwanaga A; Honma T; Yoshida T
Intern Med; 2020; 59(20):2465-2469. PubMed ID: 33055469
[TBL] [Abstract][Full Text] [Related]
27. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.
Miglio F; Valpiani D; Rossellini SR; Ferrieri A
Curr Med Res Opin; 1997; 13(10):593-601. PubMed ID: 9327194
[TBL] [Abstract][Full Text] [Related]
28. Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
DuPont HL
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():1-2. PubMed ID: 26618920
[TBL] [Abstract][Full Text] [Related]
29. Rifaximin versus metronidazole in management of acute episode of hepatic encephalopathy: An open labeled randomized clinical trial.
Mekky MA; Riad AR; Gaber MA; Abdel-Malek MO; Swifee YM
Arab J Gastroenterol; 2018 Jun; 19(2):76-79. PubMed ID: 29935863
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
[TBL] [Abstract][Full Text] [Related]
31. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.
Vlachogiannakos J; Viazis N; Vasianopoulou P; Vafiadis I; Karamanolis DG; Ladas SD
J Gastroenterol Hepatol; 2013 Mar; 28(3):450-5. PubMed ID: 23216382
[TBL] [Abstract][Full Text] [Related]
32. Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A meta-analysis.
Cao Q; Yu CB; Yang SG; Cao HC; Chen P; Deng M; Li LJ
Hepatobiliary Pancreat Dis Int; 2018 Feb; 17(1):9-16. PubMed ID: 29428113
[TBL] [Abstract][Full Text] [Related]
33. Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy.
Jain L; Sharma BC; Srivastava S; Puri SK; Sharma P; Sarin S
J Gastroenterol Hepatol; 2013 Jul; 28(7):1187-93. PubMed ID: 23425082
[TBL] [Abstract][Full Text] [Related]
34. The role of microbiota in hepatic encephalopathy.
Bajaj JS
Gut Microbes; 2014; 5(3):397-403. PubMed ID: 24690956
[TBL] [Abstract][Full Text] [Related]
35. Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species.
Yukawa-Muto Y; Kamiya T; Fujii H; Mori H; Toyoda A; Sato I; Konishi Y; Hirayama A; Hara E; Fukuda S; Kawada N; Ohtani N
Hepatol Commun; 2022 Aug; 6(8):2090-2104. PubMed ID: 35429147
[TBL] [Abstract][Full Text] [Related]
36. Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy.
Hayakawa Y; Tamaki N; Nakanishi H; Kurosaki M; Tanaka Y; Inada K; Ishido S; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Kaneko S; Yasui Y; Takahashi Y; Tsuchiya K; Okamoto R; Izumi N
Intern Med; 2023 Apr; 62(7):973-978. PubMed ID: 36070941
[TBL] [Abstract][Full Text] [Related]
37. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
[TBL] [Abstract][Full Text] [Related]
38. [Prevention and treatment of hepatic encephalopathy].
Sivolap YP
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
[TBL] [Abstract][Full Text] [Related]
39. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study.
Sanyal A; Younossi ZM; Bass NM; Mullen KD; Poordad F; Brown RS; Vemuru RP; Mazen Jamal M; Huang S; Merchant K; Bortey E; Forbes WP
Aliment Pharmacol Ther; 2011 Oct; 34(8):853-61. PubMed ID: 21848797
[TBL] [Abstract][Full Text] [Related]
40. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.
Paik YH; Lee KS; Han KH; Song KH; Kim MH; Moon BS; Ahn SH; Lee SJ; Park HJ; Lee DK; Chon CY; Lee SI; Moon YM
Yonsei Med J; 2005 Jun; 46(3):399-407. PubMed ID: 15988813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
